These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38686463)

  • 1. Effect of the sodium-glucose cotransporter-2 inhibitor, DWP16001, as an add-on therapy to insulin for diabetic dogs: A pilot study.
    An JH; Choi HS; Choi JS; Lim HW; Huh W; Oh YI; Park JS; Han J; Lim S; Lim CY; Kim TH; Moon JB; Youn HY
    Vet Med Sci; 2024 May; 10(3):e1454. PubMed ID: 38686463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium-glucose cotransporter 2 inhibitor and metformin in healthy subjects.
    Kim B; Huh KY; Hwang JG; Nah J; Huh W; Cho JM; Jang IJ; Yu KS; Kim Y; Lee S
    Br J Clin Pharmacol; 2023 Apr; 89(4):1462-1470. PubMed ID: 36422809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of safety and anti-obesity effects of DWP16001 in naturally obese dogs.
    Rhee B; Mahbubur RM; Jin C; Choi JS; Lim HW; Huh W; Park JS; Han J; Kim S; Lee Y; Park J
    BMC Vet Res; 2022 Jun; 18(1):237. PubMed ID: 35733159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.
    Jeong SI; Kim Y; Nah JJ; Huh W; Jang IJ; Hwang JG; Lee S
    Br J Clin Pharmacol; 2023 Jun; 89(6):1780-1788. PubMed ID: 36496349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent glucosuria of DWP16001, a novel selective sodium-glucose cotransporter-2 inhibitor, in healthy subjects.
    Hwang JG; Lee S; Huh W; Han J; Oh J; Jang IJ; Yu KS
    Br J Clin Pharmacol; 2022 Sep; 88(9):4100-4110. PubMed ID: 35395697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of lente insulin and NPH insulin therapy for the treatment of newly diagnosed diabetic dogs: a randomised study.
    Fracassi F; Linari G; Del Baldo F; Di Cunzolo A; D'Angelo S; Malerba E; Carotenuto G; Bonfanti U; Corradini S
    Vet Rec; 2018 Sep; 183(8):262. PubMed ID: 30030413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sodium-glucose cotransporter 2 inhibitor canagliflozin on interstitial glucose concentration in insulin-treated diabetic dogs.
    Box JR; Oyama MA; Mosenco AS; Hess RS
    J Vet Intern Med; 2024; 38(3):1353-1358. PubMed ID: 38528660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects.
    Yoon S; Park MS; Jin BH; Shin H; Na J; Huh W; Kim CO
    Expert Opin Drug Metab Toxicol; 2023; 19(7):479-485. PubMed ID: 37593838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of once daily oral administration of sodium-glucose cotransporter-2 inhibitor velagliflozin compared with twice daily insulin injection in diabetic cats.
    Niessen SJM; Kooistra HS; Forcada Y; Bjørnvad CR; Albrecht B; Roessner F; Herberich E; Kroh C
    J Vet Intern Med; 2024; 38(4):2099-2119. PubMed ID: 38884190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin.
    Choi MK; Nam SJ; Ji HY; Park MJ; Choi JS; Song IS
    Pharmaceutics; 2020 Mar; 12(3):. PubMed ID: 32183468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
    Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
    Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of insulin glargine in dogs with diabetes mellitus.
    Fracassi F; Boretti FS; Sieber-Ruckstuhl NS; Reusch CE
    Vet Rec; 2012 Jan; 170(2):52. PubMed ID: 22008227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus.
    Hadd MJ; Bienhoff SE; Little SE; Geller S; Ogne-Stevenson J; Dupree TJ; Scott-Moncrieff JC
    J Vet Intern Med; 2023; 37(3):915-924. PubMed ID: 37148170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the alpha-glucosidase inhibitor acarbose on control of glycemia in dogs with naturally acquired diabetes mellitus.
    Nelson RW; Robertson J; Feldman EC; Briggs C
    J Am Vet Med Assoc; 2000 Apr; 216(8):1265-9. PubMed ID: 10767967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review.
    Hropot T; Battelino T; Dovc K
    Horm Res Paediatr; 2023; 96(6):620-630. PubMed ID: 36279850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials.
    Rao L; Ren C; Luo S; Huang C; Li X
    Acta Diabetol; 2021 Jul; 58(7):869-880. PubMed ID: 33651228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultra-long-acting recombinant insulin for the treatment of diabetes mellitus in dogs.
    Hulsebosch SE; Pires J; Bannasch MJ; Lancaster T; Delpero A; Ragupathy R; Murikipudi S; Zion T; Gilor C
    J Vet Intern Med; 2022 Jul; 36(4):1211-1219. PubMed ID: 35621084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B; Giorgino F; Jódar E; Frias JP; Fernández Landó L; Brown K; Bray R; Rodríguez Á
    Lancet; 2021 Aug; 398(10300):583-598. PubMed ID: 34370970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.